Relja Borna, Pech Maciej
Experimentelle Radiologie, Otto-von-Guericke Universität, Leipziger Straße 44, 39120, Magdeburg, Deutschland.
Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität, Leipziger Straße 44, 39120, Magdeburg, Deutschland.
Radiologe. 2020 Aug;60(8):693-703. doi: 10.1007/s00117-020-00715-0.
Transarterial radioembolization (TARE) is a locoregional minimally invasive therapeutic strategy to treat primary and secondary hepatic neoplasia.
The objective was to assess TARE-induced immuno-oncological effects and its perspective for potential therapy improvement by using a combinatory strategy with immune checkpoint inhibitors (ICI).
Yttrium-90 (Y) TARE is used in patients with persisting liver function as the first- and second-line treatment for cholangiocarcinoma and hepatocellular carcinoma and chemotherapy refractory liver metastasis of different primaries. Combination therapy with Y TARE and ICI may synergistically improve antitumoral immunity and patient outcome. Currently, there are no clinical studies with published data regarding this combination therapy and the subsequently induced immunological effects. Clinical data on other isotopes, e.g., holmium-166 (Ho), are also lacking.
The clinical evidence of combined treatment with TARE and ICI must be considerably improved. This innovative therapy concept must be studied in new trials assessing the immunological data, including cellular phenotypes, activation, functions, and biomarkers. This may provide valid, sensitive, and specific models in order to evaluate the optimal therapy concept and/or the therapy combination for the best patient outcome.
经动脉放射性栓塞术（TARE）是一种用于治疗原发性和继发性肝脏肿瘤的局部微创治疗策略。
目的是评估TARE诱导的免疫肿瘤学效应及其通过与免疫检查点抑制剂（ICI）联合策略改善潜在治疗效果的前景。
钇-90（Y）TARE用于肝功能持续存在的患者，作为胆管癌和肝细胞癌的一线和二线治疗以及不同原发灶化疗难治性肝转移的治疗。Y TARE与ICI联合治疗可能协同改善抗肿瘤免疫和患者预后。目前，尚无关于这种联合治疗及其随后诱导的免疫效应的已发表临床研究数据。关于其他同位素，如钬-166（Ho）的临床数据也缺乏。
TARE与ICI联合治疗的临床证据必须大幅改善。这种创新的治疗理念必须在评估免疫数据（包括细胞表型、激活、功能和生物标志物）的新试验中进行研究。这可能提供有效、敏感和特异的模型，以评估最佳治疗理念和/或治疗组合，实现最佳患者预后。
